glp 1 for thyroid issues Microdosing GLP-1 Issues: Who Should Consider It? Implications of GLP-1 Receptor Agonist
Description
The Real Impact on Weight Lets talk results
Acronyms A1C - Hemoglobin A1C ADA - American Diabetes Association CVD - Cardiovascular disease DM - Diabetes mellitus FBS - Fasting blood sugar GFR - Glomerular filtration rate GI - Gastrointestinal GIP - Glucose-dependent insulinotropic polypeptide GLP-1 - Glucagon-like peptide-1 HFpEF - Heart failure with preserved ejection fraction MASH - Metabolic dysfunctionassociated steatohepatitis NASH - Nonalcoholic steatohepatitis OSA - Obstructive sleep apnea RCT - Randomized controlled trial T2DM - Type 2 diabetes mellitus Thyroid C-cell tumor = Thyroid medullary tumor DRUGS IN CLASS Dual GLP-1 and GIP agonists Tirzepatide (Zepbound) - marketed for weight loss Tirzepatide (Mounjaro) - marketed for diabetes MECHANISM OF ACTION GLP-1 and GIP Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones secreted by intestinal cells in response to eating
2,25 Interestingly, these pathological events are also manifested in the processes that lead to type 2 diabetes mellitus (T2DM) that has commonalities with AD and other neurodegenerative diseases
Their action involves normalizing the intestinal flora and reinforcing the GI barrier
This substantial reduction is set to make access to GLP-1 therapies, previously a premium treatment, far more affordable
